Filtered Image?height=270

News & Publications

News & insights

The National Security and Investment Act - a year on
Posted: 02/02/2023
Since the introduction of the National Security and Investment Act 2021 (the NSI Regime) at the beginning of 2022, the UK government has reviewed hundreds of mandatory notifications and called in many transactions for detailed national security assessments. Conditions were imposed on nine transactions and three transactions were blocked......>>
Penningtons Manches Cooper acts for SkinBioTherapeutics plc on placing and REX retail offer on AIM
Posted: 05/01/2023
The corporate team at Penningtons Manches Cooper has advised SkinBioTherapeutics plc (AIM: SBTX) on a £2.5 million placing, and a separate retail offer to existing shareholders through the REX platform, raising an additional £117,378. This is the second fundraising on AIM that Penningtons Manches Cooper has advised SkinBioTherapeutics on......>>
The Moderna v Pfizer-Biontech COVID-19 vaccine dispute: a brief explanation
Posted: 30/11/2022
Moderna’s patent infringement claim against Pfizer and BioNTech about its COVID-19 vaccine technology has been widely reported. After filing lawsuits in August 2022 in the US and Germany, Moderna has now launched related proceedings in the UK Patents Court. In response, Pfizer and BioNTech have issued separate UK claims......>>
Same old, same old but different: the proposed UK framework for medical device regulations
Posted: 21/11/2022
The Medicines and Healthcare products Regulatory Agency (MHRA) published its consultation response in June 2022. To the relief of the majority of stakeholders in this area, this will result in new regulations for the United Kingdom that broadly align with the EU Medical Devices Regulations and the In Vitro Diagnostic Device Regulations......>>
Penningtons Manches Cooper advises Seloxium on its spin-out from Oxford University
Posted: 07/11/2022
The corporate team at Penningtons Manches Cooper has advised Seloxium on the completion of its spin-out from Oxford University and initial seed funding led by Oxford Science Enterprises in cooperation with Oxford University Innovation, the University’s technology transfer office......>>

Read all life sciences news & insights

Publications

E-Bulletins

BioBrief - May 2022
Welcome to the spring edition of BioBrief. We start this edition with an article I wrote recently for OBN Connect magazine which covers the challenges faced by Biotech founders on spin-out and the career change it requires. This is something that I am familiar with as I changed my career from project manager of global clinical trials for IQVIA to being an IP lawyer.

BioBrief - Winter 2021
Welcome to the winter edition of BioBrief. It has certainly been a very busy year for the life sciences industry! Colleagues across our team have been involved in interesting projects, in particular in terms of commercial deals and corporate transactions. We are delighted to report that, amongst others, we advised the shareholders of molecular diagnostics company ATDBio on its sale to NASDAQ Stockholm listed Biotage AB for approximately £45m..

Life sciences update – Spring 2021
In this Spring edition of BioBrief, we discuss a variety of topics, one of which includes the ‘chocolate teapot’ theory included in the recent Illumina v MGI judgment.

Life sciences update – Autumn 2020
In this issue: With the clocks set to go back this weekend, it will be a ceremonious reminder that the end of the year is looming and with it, the end of the Brexit transition period. Please keep an eye out for further briefings/updates on our website over the coming months.

Life sciences update - Summer 2019
In this issue: It’s a busy time of year in the life sciences event calendar, including the recent OBN ‘BioTrinity’ conference in London, and forthcoming One Nucleus ‘ON Helix’ conference.

View all life sciences e-bulletins

Return to Life sciences

Filter publications

Filter by keyword: Filter by expertise: Filter by publication type:

In this section

Media enquiries

Contact our press team on:

+44 (0)20 7457 3258
+44 (0)7887 888105 (out of hours)

Useful links

Value

Contact an office

London (Head office)
+44 (0)20 7457 3000
Basingstoke
+44 (0)1256 407100
Birmingham
+44 (0)121 312 2560
Cambridge
+44 (0)1223 465465
Guildford
+44 (0)1483 791800
Oxford
+44 (0)1865 722106
Reading
+44 (0)118 982 2640

Madrid
+34 91 781 6670
Paris
+33 1 44 34 24 80
Piraeus
+30 210 361 4840
Singapore
+65 6438 4497

Sectors

Services for Business

Services for Individuals

Copyright

© 2023 Penningtons Manches Cooper LLP.
All rights reserved.
Website design by Frontmedia / Dynamic Pear

Penningtons Manches Cooper LLP

Penningtons Manches Cooper LLP is a limited liability partnership registered in England and Wales with registered number OC311575 and is authorised and regulated by the Solicitors Regulation Authority.